medicinal chemistry capabilities and expediting the screening, selection, and development of industry partners’ drug candidates. With operations in San Diego, California, and Budapest, Hungary, BioBlock’s talented group of world standard chemists along with more than a century of combined pharma and contract research organization expertise will operate in partnership with GD3’s current platform of chemistry services focused on uHTS, computational chemistry, and structural biology.
Dr. Peter Pallai, CEO of BioBlocks, expressed delight over the collaboration. He said, “We welcome the opportunity to become a member of the Genesis family of companies after 20 years of building an organization with strengths in medicinal chemistry expertise and collaborative drug discovery. By combining the complementary CRO capabilities of GD3 members and BioBlocks, we are creating a most comprehensive coverage of the drug discovery spectrum that will provide exceptional services to our pharma/biotech partners.”
Dr. Eli Mordechai, CEO of GBG, expressed hopes for progress in the future. He said, “We constantly adapt our services to meet the needs of our industry partners. I believe that adding BioBlocks’ sector expertise and global reach is another way to differentiate our capabilities and significantly enhance our portfolio around medical chemistry to better serve our industry partners.”
Ben Bandaru, Ph.D., Director of Corporate Development for GBG, expressed optimism over the acquisition. He also revealed the future expansion plans of the company. He said, “While we continue to add complementary services to expand into new markets, we are also adding scale to increase market share with our existing services. The acquisition of BioBlocks is our first foray into establishing a base in the epicenter of European Biotech and Pharma, which seemed like our logical next step.”
